Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$11.3 million.

  • Cardiff Oncology's Consolidated Net Income rose 507.59% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.4 million, marking a year-over-year decrease of 1745.82%. This contributed to the annual value of -$45.4 million for FY2024, which is 979.37% down from last year.
  • Cardiff Oncology's Consolidated Net Income amounted to -$11.3 million in Q3 2025, which was up 507.59% from -$13.9 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Consolidated Net Income ranged from a high of -$5.4 million in Q1 2021 and a low of -$13.9 million during Q2 2025
  • In the last 5 years, Cardiff Oncology's Consolidated Net Income had a median value of -$10.4 million in 2022 and averaged -$10.3 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first tumbled by 10349.14% in 2022, then soared by 1696.81% in 2024.
  • Cardiff Oncology's Consolidated Net Income (Quarter) stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then grew by 0.72% to -$9.3 million in 2023, then dropped by 26.39% to -$11.8 million in 2024, then grew by 4.47% to -$11.3 million in 2025.
  • Its Consolidated Net Income stands at -$11.3 million for Q3 2025, versus -$13.9 million for Q2 2025 and -$13.4 million for Q1 2025.